Overcoming Treatment Toxicity through Sequential Therapy

Combined inhibitions of PARP and DNA damage checkpoint have the potential for high anti-cancer efficacy, but concurrent inhibitions have been hampered by intolerable side effects. In this issue of Cancer Cell , Fang and colleagues ( Fang et al., 2019 ) propose that sequential inhibitions of PARP and DNA damage checkpoint considerably widen the therapeutic window.